CoChat
Sign Up
Cited by 249Liver Disease Diagnosis and TreatmentPsoriasis: Treatment and PathogenesisLiver Diseases and Immunity

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis

Miele, Luca, Vallone, Selenia, Cefalo, Consuelo, La Torre, Giuseppe, Di Stasi, Carmine, Vecchio, Fabio M., D’Agostino, Magda, Gabrieli, Maria L., Vero, Vittoria, Biolato, Marco, Pompili, Maurizio, Gasbarrini, Giovanni, Rapaccini, Gianludovico, Amerio, Pierluigi, De Simone, Clara, Grieco, Antonio·2009·Journal of Hepatology
DOI 10.1016/j.jhep.2009.06.008
Open this paper in CoChat — free account

Abstract

Background/aims The association between NAFLD and psoriasis has never been explored in prospective epidemiological studies. The aim of this 2-phase study was to study the clinical features of NAFLD in patients with psoriasis.Methods Phase 1: Investigation of prevalence and characteristics of NAFLD in an unselected cohort of 142 adult Italian outpatients with psoriasis vulgaris. Phase 2: Comparison of the psoriasis cohort subgroup with NAFLD and an age- and body mass index-matched retrospective cohort of 125 non-psoriasis patients with biopsy proven NAFLD.Results Based on histories, laboratory tests, and ultrasound studies, 84 (59.2%) received clinical diagnosis of NAFLD; 30 had factors potentially associated with liver disease other than NAFLD (e.g., viral hepatitis, significant ethanol, methotrexate use); and 28 (19.7%) had normal livers. Comparison of the normal-liver and NAFLD subgroups revealed that NAFLD in psoriasis patients (Ps-NAFLD) was significantly correlated with metabolic syndrome (p<0.05); obesity (p=0.043); hypercholesterolemia (p=0.029); hypertriglyceridemia (p<0.001); AST/ALT ratio >1 (p=0.019), and psoriatic arthritis (PsA) (p=0.036). The association with PsA remained significant after logistic regression analysis (OR=3.94 [CI, 1.07-14.46]). Compared with the retrospective non-psoriatic NAFLD cohort (controls), Ps-NAFLD patients (cases) were likely to have severe NAFLD reflected by non-invasive NAFLD Fibrosis Scores and AST/ALT >1.Conclusions NAFLD is highly prevalent among psoriasis patients, where it is closely associated with obesity (overall and abdominal), metabolic syndrome, and PsA, and more likely to cause severe liver fibrosis (compared with nonPs-NAFLD). Routine work-up for NAFLD may be warranted in patients with psoriasis, especially when potentially hepatotoxic drug therapy is being considered.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2009.06.008

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Ryan, 2004, Methotrexate monitoring: a countrywide analysis of monitoring policies among dermatologists and rheumatologists in the republic of Ireland, Rheumatology, 43, ii50

Cited by

Sorted by citations

Items 201–249 of 249

Related

See all

Metadata

Authors
Miele, L., Vallone, S., Cefalo, C., La Torre, G., Di Stasi, C., Vecchio, F. M., D’Agostino, M., Gabrieli, M. L., Vero, V., Biolato, M., Pompili, M., Gasbarrini, G., Rapaccini, G., Amerio, P., De Simone, C., & Grieco, A.
Affiliations
Università Cattolica del Sacro Cuore (IT)
Corresponding author
Grieco, Antonio
ORCID
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2009-10
Volume
51
Issue
4
Pages
778-786
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/j.jhep.2009.06.008
OpenAlex
W2013886298
Cited by
249
References
39
Citations by year
2026: 7 · 2025: 7 · 2024: 13 · 2023: 9 · 2022: 13 · 2021: 18 · 2020: 45 · 2019: 19 · 2018: 13 · 2017: 16 · 2016: 11 · 2015: 13 · 2014: 15 · 2013: 9 · 2012: 13
FWCI
8.77
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, plaque psoriasis, psoriatic arthritis, metabolic syndrome, obesity, hypertriglyceridemia, hypercholesterolemia, liver fibrosis, AST/ALT ratio, hepatotoxic drugs, prevalence, NAFLD severity
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Chronic Disease, Cross-Sectional Studies, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Obesity, Psoriasis, Cohort Studies, Arthritis, Psoriatic, Case-Control Studies, Metabolic Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review